Will the FDA approve Roche’s Enspryng for thyroid eye disease at its October 15 review?

Question

This market will resolve YES if the FDA issues a marketing approval for Roche’s Enspryng (satralizumab) covering thyroid eye disease in the review cycle with the announced target date of 2026-10-15. The legally effective approval and authorised indication control, not the date the medicine reaches pharmacies. Approval for MOGAD or the existing neuromyelitis optica indication does not satisfy this question.

The relevant approval must be dated no later than 2026-10-15 at 23:59 America/New_York. A

Problyx · Accepted Answer

Yes — the community forecast puts this at 81%.

Problyx · Answer

No — the community forecast puts this at 19%.